Recently, MOMED Biotech Co., Ltd. (hereinafter referred to as "MOMED Biotech") and Zhejiang XIANJU PHARMA Co., Ltd. (hereinafter referred to as "XIANJU PHARMA") have carried out cooperation in early research and development services and jointly launched a molecular design project for new hormonal drugs. 

 Both sides will deeply integrate the powerful computing ability and high efficiency and accuracy of MOMED Biotech's "MechGen" multi-dimensional intelligent technology platform with the profound technological accumulation of XIANJU PHARMA in the field of drug research and development, so as to jointly promote the research and development of small molecule hormonal drugs.

The cooperation between MOMED Biotech and XIANJU PHARMA will utilize cutting-edge computational biology and AI technologies to accelerate the R&D process of new drug molecules. Both sides are looking forward to overcoming traditionally difficult drug targets through this cooperation.

XIANJU PHARMA (www.xjpharma.com) is a leading high-tech enterprise that comprehensively produces raw materials and preparations for steroid drugs. Since its establishment in 1972, the company has been focusing on the field of steroid hormones, cooperating with scientific research institutions at home and abroad to promote technological innovation and gradually integrating with international new drug development. With the vision of "becoming one of the top ten steroid drug suppliers in the world", XIANJU PHARMA advocates a culture of authenticity, win-win and innovation, and is committed to enhancing innovation and profitability, thus contributing to the cause of human health.

MOMED Biotech (www.momed.com.cn) is the world's first biotechnology company that takes the mechanism research of drug targets as the driving force and combines advanced artificial intelligence technologies to conduct research and development of innovative drugs. MOMED Biotech uses the computational biology method that has won the Nobel Prize to study the working mechanism of target proteins, thus achieving a methodological leap at the AI data end. The MechGen drug research and development platform of MOMED Biotech integrates the industry-leading computational biology and AI drug design technologies, providing a variety of preclinical drug discovery services for the industry.